Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy

European Heart Journal

Volumn 35, Issue 1, 2014, Pages 33-41

  Miyamoto, Shelley D ^a   Stauffer, Brian L ^a,b,c   Nakano, Stephanie ^a   Sobus, Rebecca ^b   Nunley, Karin ^b   Nelson, Penny ^b   Sucharov, Carmen C ^b  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

b Adrenergic receptor; CaMK; Fetal gene programme; Paediatric dilated cardiomyopathy; Phosphatase

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CONNEXIN 43; CYCLIC AMP; PHOSPHATASE; PHOSPHOLAMBAN;

ADAPTATION; ADOLESCENT; ADULT; ARTICLE; CHILD; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEART FAILURE; HUMAN; HUMAN TISSUE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD;

CAMK; FETAL GENE PROGRAMME; PAEDIATRIC DILATED CARDIOMYOPATHY; PHOSPHATASE; Β-ADRENERGIC RECEPTOR;

ADAPTATION, PHYSIOLOGICAL; CALCIUM-BINDING PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CHILD; CONNEXIN 43; CYCLIC AMP; DOWN-REGULATION; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PHOSPHORYLATION; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84891766294     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs229     Document Type: Article

References (42)

1. Wilkinson JD, Landy DC, Colan SD, Towbin JA, Sleeper LA, Orav EJ, Cox GF, Canter CE, Hsu DT, Webber SA, Lipshultz SE. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin 2010;6:401-413, vii.
2. de Giuli F, Khaw KT, Cowie MR, Sutton GC, Ferrari R, Poole-Wilson PA. Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696 884 in the united kingdom. Eur J Heart Fail 2005;7:295-302. (Pubitemid 40249521)
3. Kirk R, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Dobbels F, Rahmel AO, Stehlik J, Hertz MI. The registry of the international society for heart and lung transplantation: thirteenth official pediatric heart transplantation report-2010. J Heart Lung Transplant 2010;29:1119-1128.
4. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296: 1867-1876. (Pubitemid 44596196)
5. Kantor PF, Abraham JR, Dipchand AI, Benson LN, Redington AN. The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy. J Am Coll Cardiol 2010;55:1377-1384.
6. Konstam MA. Improving clinical outcomes with drug treatment in heart failure: what have trials taught? Am J Cardiol 2003;91:9D-14D. (Pubitemid 36369330)
7. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007;298:1171-1179. (Pubitemid 47403103)
8. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-211. (Pubitemid 12079105)
9. Staley NA, Noren GR, Einzig S, Rublein TG. Effect of early propranolol treatment in an animal model of congestive cardiomyopathy: I mortality and Ca2+ transport in sarcoplasmic reticulum. Cardiovasc Res 1984;18:371-376. (Pubitemid 14108093)
10. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003;93:896-906. (Pubitemid 37433227)
11. Hoch B, Meyer R, Hetzer R, Krause EG, Karczewski P. Identification and expression of delta-isoforms of the multifunctional Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human myocardium. Circ Res 1999;84:713-721. (Pubitemid 29157339)
12. Calalb MB, McKinsey TA, Newkirk S, Huynh K, Sucharov CC, Bristow MR. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. Clin Transl Sci 2009;2:325-332.
13. Witcher DR, Kovacs RJ, Schulman H, Cefali DC, Jones LR. Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem 1991;266:11144-11152. (Pubitemid 21906924)
14. Dzhura I, Wu Y, Colbran RJ, Balser JR, Anderson ME. Calmodulin kinase determines calcium-dependent facilitation of l-type calcium channels. Nat Cell Biol 2000;2:173-177.
15. Le Peuch CJ, Haiech J, Demaille JG. Concerted regulation of cardiac sarcoplasmic reticulum calcium transport by cyclic adenosine monophosphate dependent and calcium-calmodulin-dependent phosphorylations. Biochemistry 1979;18: 5150-5157. (Pubitemid 10215977)
16. Zhang T, Miyamoto S, Brown JH. Cardiomyocyte calcium and calcium/calmodulindependent protein kinase II: friends or foes? Recent Prog Horm Res 2004;59:141-168. (Pubitemid 41327150)
17. Boknik P, Fockenbrock M, Herzig S, Knapp J, Linck B, Luss H, Muller FU, Muller T, Schmitz W, Schroder F, Neumann J. Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation. Naunyn Schmiedebergs Arch Pharmacol 2000;362:222-231.
18. Aoyama H, Ikeda Y, Miyazaki Y, Yoshimura K, Nishino S, Yamamoto T, Yano M, Inui M, Aoki H, Matsuzaki M. Isoform-specific roles of protein phosphatase 1 catalytic subunits in sarcoplasmic reticulum-mediated Ca2+ cycling. Cardiovasc Res 2011;89:79-88.
19. Lompre AM, Schwartz K, d'Albis A, Lacombe G, Van Thiem N, Swynghedauw B. Myosin isoenzyme redistribution in chronic heart overload.Nature 1979;282:105-107. (Pubitemid 10250124)
20. Engel G, Hoyer D, Berthold R, Wagner H. (+/-)[125iodo] cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig. Naunyn Schmiedebergs Arch Pharmacol 1981; 317:277-285. (Pubitemid 12247877)
21. SucharovCC,Dockstader K,McKinseyTA.Yy1 protects cardiacmyocytes frompathologic hypertrophy by interacting with hdac5. Mol Biol Cell 2008;19:4141-4153.
22. Sucharov CC, Mariner P, Long C, Bristow M, Leinwand L. Yin yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter. J Biol Chem 2003;278:31233-31239. (Pubitemid 36994640)
23. Bristow MR, Feldman AM. Changes in the receptor-g protein-adenylyl cyclase system in heart failure from various types of heart muscle disease. Basic Res Cardiol 1992;87(Suppl. 1):15-35.
24. Herron TJ, McDonald KS. Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res 2002;90:1150-1152. (Pubitemid 34786898)
25. Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000;86:386-390. (Pubitemid 30141756)
26. White M, Roden R, Minobe W, Khan MF, Larrabee P, Wollmering M, Port JD, Anderson F, Campbell D, Feldman AM. Age-related changes in beta-adrenergic neuroeffector systems in the human heart. Circulation 1994;90:1225-1238. (Pubitemid 24284444)
27. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S. Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor downregulation in heart failure. Circ Res 1986;59:297-309. (Pubitemid 17178124)
28. Ross RD, Daniels SR, Schwartz DC, Hannon DW, Shukla R, Kaplan S. Plasma norepinephrine levels in infants and children with congestive heart failure. Am J Cardiol 1987;59:911-914. (Pubitemid 17061313)
29. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, Crow MT. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3?-kinase. Circ Res 2000; 87:1172-1179.
30. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)-and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive g protein. Circulation 1999;100:2210-2212.
31. Port JD, Bristow MR. Adrenergic receptor coupling and uncoupling in heart failure. In: Richard A, Walsh MD, ed. Molecular Mechanisms for Cardiac Hypertrophy and Failure. Oxford: Taylor & Francis 2005:323-340.
32. Wang WC, Juan AH, Panebra A, Liggett SB. Microrna let-7 establishes expression of beta2-adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation. Proc Natl Acad Sci USA 2011;108:6246-6251.
33. He JQ, Balijepalli RC, Haworth RA, Kamp TJ. Crosstalk of beta-adrenergic receptor subtypes through Gi blunts beta-adrenergic stimulation of l-type Ca2+ channels in canine heart failure. Circ Res 2005;97:566-573. (Pubitemid 41361747)
34. Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 2011;51:468-473.
35. Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase ii inhibition protects against structural heart disease. Nat Med 2005;11: 409-417. (Pubitemid 40562331)
36. Ling H, Zhang T, Pereira L, Means CK, Cheng H, Gu Y, Dalton ND, Peterson KL, Chen J, Bers D, Heller Brown J. Requirement for Ca2+/calmodulin-dependent kinase ii in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest 2009;119:1230-1240.
37. Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, Zimmermann N. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol 1997;29:265-272. (Pubitemid 27129150)
38. Saffitz JE. Douglas p. Zipes lecture. Biology and pathobiology of cardiac connexins: from cell to bedside. Heart Rhythm 2006;3:102-107. (Pubitemid 43071901)
39. Rhee EK, Canter CE, Basile S, Webber SA, Naftel DC. Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome? J Heart Lung Transplant 2007;26:447-452. (Pubitemid 46604801)
40. Ationu A, Sorensen K, Whitehead B, Singer D, Burch M, Carter ND. Ventricular expression of brain natriuretic peptide gene following orthotopic cardiac transplantation in children-a three year follow up. Cardiovasc Res 1993;27: 2135-2139. (Pubitemid 24034725)
41. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87: 1402-1412.
42. Auerbach SR, Richmond ME, Lamour JM, Blume ED, Addonizio LJ, Shaddy RE, Mahony L, Pahl E, Hsu DT. Bnp levels predict outcome in pediatric heart failure patients: post hoc analysis of the pediatric carvedilol trial. Circ Heart Fail 2010;3:606-611.